Infusion Treatments for Gastric Cancer

If “infusion treatment” sounds like something you’d order at a fancy coffee shop (“One oat-milk immune-boosting infusion, extra foam!”), you’re not alone.
In cancer care, infusion simply means medication delivered through a vein (IV) over minutes to hoursusually in a clinic, sometimes at home with a pump, and
occasionally while you scroll on your phone pretending you’re not watching the IV drip like it’s a suspense series.

For gastric (stomach) cancer, infusion therapies often include IV chemotherapy, targeted therapy, and immunotherapysometimes used alone, often used in
combination depending on the cancer’s stage, location (stomach vs. gastroesophageal junction), and biomarker results (like HER2 or PD-L1). These treatments
can be given before surgery, after surgery, with radiation, or for advanced/metastatic disease to control cancer and symptoms. This article breaks down the
most common infusion approaches, what “a typical infusion day” looks like, and practical tips for navigating treatment.

What counts as an “infusion treatment” for gastric cancer?

Infusion treatment usually means drugs delivered directly into the bloodstream via an IV. In gastric cancer care, infusion therapies most commonly include:

• IV chemotherapy (cytotoxic drugs that damage fast-growing cancer cells)
• IV targeted therapy (drugs that target specific features of the tumor, such as HER2)
• IV immunotherapy (drugs that help your immune system recognize and attack cancer)
• Supportive infusions (hydration, electrolytes, anti-nausea meds, iron, or other symptom-focused treatments)

Some stomach-cancer medications are pills (like certain chemo agents), but many cornerstone treatments are still delivered by infusionespecially combination
regimens and biologic therapies.

The big picture: how doctors decide which infusions you get

Treatment planning for gastric cancer is typically stage-driven (how far the cancer has spread) and biology-driven (what the tumor “looks like” at a molecular
level). National Cancer Institute resources describe chemotherapy, immunotherapy, and targeted therapy as key options, with biomarker testing helping predict
which patients may benefit from specific drugs. In other words: it’s not just “stomach cancer,” it’s your stomach cancer.

Common factors that shape infusion choices

• Stage and resectability: Is the cancer removable with surgery, or unresectable/metastatic?
• Goals of care: Cure (often in earlier stages) vs. control and quality of life (often in advanced disease)
• Biomarkers: HER2 status, PD-L1 expression, MSI-H/dMMR status, and other markers your team may test
• Overall health: Nutrition, kidney function, nerve health, heart function, and performance status
• Prior treatments: What you’ve already received and how the cancer responded

Infusion chemotherapy for gastric cancer

Chemotherapy for stomach cancer often uses a combination of drugs. The American Cancer Society lists several commonly used chemo medicines, including 5-FU
(fluorouracil), capecitabine (often oral), cisplatin, oxaliplatin, docetaxel, paclitaxel, irinotecan, and others. Not every patient gets every drugthink of
these as items on a menu, not a mandatory tasting flight.

Perioperative infusion chemo (before and after surgery)

For many people with localized, resectable gastric or gastroesophageal junction cancers, chemotherapy may be given before surgery to shrink the tumor and
treat microscopic disease, then repeated after surgery. A widely used regimen in this setting is FLOT (5-FU, leucovorin, oxaliplatin, and
docetaxel). Major cancer centers describe FLOT as a common approach for localized disease treated with surgery plus chemotherapy.

What FLOT looks like in real life varies by institution, but it’s typically delivered in cycles every couple of weeks, sometimes with a portable pump for part
of the 5-FU infusion. Expect labs before each cycle and dose adjustments if side effects stack up.

Infusion chemo for advanced/metastatic gastric cancer

When gastric cancer is metastatic or unresectable, infusion chemotherapy is often used to slow growth, reduce symptoms, and help you maintain function.
Common backbone combinations often include a fluoropyrimidine (like 5-FU) plus a platinum drug (like oxaliplatin or cisplatin). Additional agents may be
added depending on biomarkers and treatment goals.

Second-line and later infusion options

If the cancer progresses, oncologists may switch to another infusion regimen. Examples include paclitaxel-based therapy, irinotecan-based therapy, or other
combinations depending on your prior exposure, side effects, and tumor biology. The key is sequencing: getting the most benefit while protecting quality of
life.

Targeted infusion therapy: treating the tumor’s “specific knobs and switches”

Targeted therapies focus on features that are more common in cancer cells than normal cells. NCI explains targeted therapy as treatment that interferes with
specific proteins or pathways that help tumors grow and spread.

HER2-positive gastric cancer: trastuzumab-based infusion therapy

If your tumor is HER2-positive, targeted therapy may be added to chemotherapy. Trastuzumab is a well-known HER2-targeted antibody that is
delivered by infusion. Some patients later receive antibody-drug conjugatestargeted antibodies that deliver a chemotherapy payload directly to HER2-expressing
cells.

One such drug is fam-trastuzumab deruxtecan-nxki (Enhertu), which the FDA approved for adults with locally advanced or metastatic
HER2-positive gastric or GEJ adenocarcinoma after prior trastuzumab-based therapy.

Anti-angiogenic therapy: ramucirumab

Another targeted infusion option in gastric cancer care is ramucirumab, an antibody that targets pathways involved in tumor blood-vessel
growth. It may be used in certain later-line settings and is often paired with chemotherapy depending on the situation and your oncologist’s strategy.

Immunotherapy infusions: recruiting your immune system

Immunotherapy is a broad category, but for gastric cancer the most common infusion immunotherapies are immune checkpoint inhibitors. The National Cancer
Institute lists nivolumab and pembrolizumab as immunotherapy drugs used to treat stomach cancer, with biomarker testing often
guiding selection.

Nivolumab + chemotherapy (first-line metastatic setting)

In the United States, the FDA approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric
cancer, GEJ cancer, and esophageal adenocarcinoma.

Pembrolizumab in selected situations

Pembrolizumab is another checkpoint inhibitor used in certain advanced stomach cancers, particularly when biomarkers suggest a higher likelihood of response.
Your team may discuss PD-L1 testing, MSI-H/dMMR status, and other factors when considering pembrolizumab.

How infusion is delivered: IVs, ports, and PICC lines

Infusion therapy can be delivered through a temporary IV in your arm, but many patients receiving multi-cycle chemo (or drugs that can irritate veins) use a
more durable access device.

The American Cancer Society explains that IV therapy (infusion therapy) delivers medicines and fluids into the bloodstream and describes several access
optionssuch as peripheral IVs and implanted ports.

Peripheral IV

Best for short infusions or limited cycles. Downsides: repeated needle sticks and sometimes “difficult access” days where your veins play hide-and-seek.

Port (port-a-cath)

A small device under the skin, usually on the chest, accessed with a special needle. Many patients like ports because they reduce repeated IV attempts and can
handle longer or harsher infusions.

PICC line

A longer catheter placed in the arm with the tip in a large vein. Useful for ongoing therapy, though it requires diligent line care and may limit some
activities.

What happens on infusion day?

Every center has its own flow, but most infusion visits follow a familiar rhythm:

1. Check-in and vitals (blood pressure, temperature, weight)
2. Lab work to confirm it’s safe to proceed (blood counts, liver/kidney function, electrolytes)
3. Premedications to prevent nausea, allergic reactions, or infusion-related symptoms
4. The infusion itself (minutes to hours depending on regimen)
5. Observation and discharge with home meds and symptom instructions

Pro tip: bring a “clinic kit”charger, headphones, a snack (if allowed), and something that makes time pass faster. The IV pole is not a dance partner, no
matter how much it follows you.

Side effects: what’s common and what’s urgent

Side effects depend on the drugs used and your individual tolerance. Chemotherapy can affect fast-growing normal cells, which is why nausea, mouth sores,
diarrhea, and low blood counts can happen.

Chemo infusion side effects to watch

• Low blood counts (infection risk, anemia, bleeding risk)
• Nausea/vomiting (often preventable with modern antiemetics)
• Neuropathy (tingling/numbness, especially with oxaliplatin)
• Fatigue (the “why is brushing my teeth a workout?” effect)
• Mouth sores and appetite changes

Targeted therapy and immunotherapy side effects

Targeted therapies and immunotherapies can have different side effect patterns than traditional chemotherapy. Cancer.Net notes that targeted therapy side
effects vary widely by drug and target. Immunotherapy can cause immune-related inflammation in organs (skin, gut, liver, lungs, endocrine glands), which needs
prompt attention.

Call your care team urgently if you have:

• Fever (especially with low white blood cell counts)
• Shortness of breath, chest pain, or sudden cough
• Severe diarrhea, dehydration, or inability to keep fluids down
• Confusion, severe weakness, or uncontrolled pain
• New rash with swelling, blistering, or facial swelling

Supportive infusions: the unsung heroes

Not every infusion is “anti-cancer,” but many are “anti-misery,” which counts for a lot. Depending on your situation, your team might use:

• IV fluids for dehydration or kidney support
• Electrolytes (like magnesium or potassium) if levels drop
• IV anti-nausea medications when oral meds aren’t enough
• Iron infusions for iron-deficiency anemia (in selected cases)
• Nutrition support strategies when eating becomes difficult

Questions to ask your oncologist before starting infusion therapy

• What’s the goal of this regimen: cure, shrink before surgery, prevent recurrence, or control symptoms?
• Which biomarkers were tested (HER2, PD-L1, MSI-H/dMMR), and how do they change my options?
• How many cycles are planned, and how will we measure whether it’s working?
• What side effects are most likely with my specific regimenand what can we do to prevent them?
• Do I need a port or PICC line?
• What symptoms mean “call today” vs. “mention at the next visit”?
• Are there clinical trials that fit my stage and biomarkers?

Clinical trials and emerging infusion approaches

Clinical trials continue to refine how infusion therapies are combined and timedespecially immunotherapy with chemotherapy in earlier stages. NCI maintains
searchable listings of gastric cancer treatment trials, and large cancer centers frequently run studies that add or sequence immunotherapy around surgery.

If you’re interested, ask your team to explain the “why” behind a trial: what it’s testing, what’s standard of care either way, and what extra visits or
risks it may involve.

Conclusion

Infusion treatments for gastric cancer are more than “chemo in a chair.” They’re a toolkitIV chemotherapy regimens that attack rapidly dividing cells,
targeted therapies that home in on tumor features like HER2, and immunotherapies that help your immune system do what it was built for. The smartest plan is
individualized: stage, biomarkers, and your overall health guide which infusions make sense and in what order. If you take away one practical step, let it be
this: ask for your biomarker results and have your oncologist explain how those results unlock (or rule out) specific infusion options.

Real-World Experiences With Infusion Treatments for Gastric Cancer (About )

People often expect infusion therapy to feel like a dramatic movie momentteary speeches, slow-motion IV drips, and inspirational background music. Real life
is usually more ordinary (and honestly, that can be comforting). Many patients describe infusion days as a strange blend of “medical appointment” and “airport
layover”: you pack snacks, charge devices, wait for labs, and then settle in while medication runs.

One of the most common experiences patients share is how much the routine matters. The first infusion can feel overwhelming because
everything is newnames of drugs, pump alarms, premedications, and a dozen instructions delivered while you’re trying to remember your own birthday. But by
the second or third cycle, people often find a rhythm: a favorite hoodie for cold infusion rooms, a specific playlist, and a “treatment day schedule” that
reduces anxiety. Some even mark infusion days with small rewards: a favorite takeout meal afterward, a new audiobook chapter, or a guilt-free nap.

Another frequent theme is the learning curve around side effects. Many patients say nausea is less scary once they realize it can be managed
proactivelytaking anti-nausea meds on schedule, not waiting until symptoms are severe, and keeping “safe foods” around (plain rice, soup, crackers, whatever
your stomach tolerates). Fatigue is often described as different from normal tirednessmore like your body quietly demanding a software update. Patients who
cope best tend to treat rest as a plan, not a failure: short walks when possible, consistent sleep routines, and realistic expectations for work and chores.

People with ports often report a mix of relief and annoyance. Relief because repeated IV sticks are reduced; annoyance because it’s one more “thing” to live
with and protect. Many patients feel more confident after a nurse walks them through port care, signs of infection to watch for, and what is normal soreness
versus what needs a call. It’s common to feel squeamish at firstand then, surprisingly, to treat it like a practical tool, the same way you’d treat a
seatbelt: not glamorous, but it does the job.

Patients receiving immunotherapy infusions often describe fewer day-to-day side effects than traditional chemo, but also a lingering worry: “What if my immune
system gets too excited?” That’s why people emphasize staying in close contact with the care team about new symptoms like rash, diarrhea, cough, or unusual
fatigue. The shared wisdom is simple: don’t tough it out in silence; call early. In real-world terms, early reporting can turn a big problem into a small
detour.

Finally, many patients say the most meaningful “support” isn’t always big gesturesit’s the friend who drives them, the family member who learns the calendar,
the coworker who doesn’t make it weird, and the nurse who explains things twice without making you feel like you asked a dumb question. Gastric cancer
treatment is hard, but infusion therapy is also where people often discover how much care can be deliveredthrough medicine, yes, but also through routine,
teamwork, and small, steady choices.